NIPH Clinical Trials Search

Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Type 2 diabetes
Date of first enrollment	2013/06/01
Target sample size	20
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	teneligliptin

Outcome(s)

Primary Outcome	Change in Glycosylated hemoglobin(HbA1c) levels over 12 weeks,Change in DPP-4 activity
Secondary Outcome	Active Glucagon-like peptide-1 (GLP-1) concentration,Active Gastric inhibitory Polypeptide (GIP) concentration,Glucagon levels,Postprandial (1 and 2 hour) glucose levels,Fasting blood glucose levels,Insulin levels

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	(1) Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions such as Cushing's syndrome and acromegaly (2) Application of contraindications contained in the package insert (3) Excessive alcohol consumption : mean daily intake of pure alcohol >=60g (4) Pregnant women, women suspected of being pregnant, or lactating women (5) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason